XML 35 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring and Related Charges
9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Related Charges

16. Restructuring and Related Charges

In April 2024, following a strategic review of the combined business after completion of the Merger, the Company announced a workforce reduction plan (the "Strategic Reorganization") to reduce operating costs and focus on long-term growth opportunities. Under this Strategic Reorganization, the Company reduced its workforce by approximately 10% of its total workforce, with the majority of these employees separating by July 2024. Employees who were impacted by the Strategic Reorganization were eligible to receive severance and other benefits contingent upon an impacted employee's execution of a separation agreement. Certain impacted employees were covered by employment agreements or existing severance plans that provided termination benefits.

One-time termination benefits were recorded pursuant to ASC 420, Exit or Disposal Cost Obligations, while termination benefits under ongoing benefit arrangement were recorded pursuant to ASC 712, Compensation - Nonretirement Postemployment Benefits.

The Company recognized restructuring charges of approximately $2.3 million and $12.4 million during the three and nine months ended September 30, 2024, respectively, related to a restructuring plan implemented after the Merger to integrate operations and realize synergies.

For the three and nine months ended September 30, 2023, the Company recognized restructuring and related charges of $2.0 million and $5.4 million, respectively, related to a restructuring plan implemented in 2022 to improve the Company's operational efficiency.

The Company also continues to recognize ongoing restructuring charges from its restructuring plans for facility-related costs, which will continue through the termination of the facility leases.

The following table summarizes the change in the Company’s restructuring and other related liabilities for the nine months ended September 30, 2024 (in thousands):

 

 

 

Severance
and other
employee-
related
benefits
(1)

 

 

Facility
Costs

 

 

Other(2)

 

 

Total

 

Balance at December 31, 2023

 

$

825

 

 

$

 

 

$

 

 

$

825

 

Restructuring and related charges

 

 

9,522

 

 

 

2,108

 

 

 

744

 

 

 

12,374

 

Cash payments

 

 

(7,806

)

 

 

(2,108

)

 

 

(744

)

 

 

(10,658

)

Balance at September 30, 2024

 

$

2,541

 

 

$

 

 

$

 

 

$

2,541

 

 

(1)
Restructuring liabilities are recorded in accrued liabilities on the condensed consolidated balance sheets. Substantially all severance and other employee-related benefits related to ongoing benefit arrangements and were recorded pursuant to ASC 712.
(2)
Other restructuring liabilities are comprised mainly of sublease commissions and are recorded in other accrued liabilities on the condensed consolidated balance sheets.

The Company’s restructuring and related charges by segment and corporate were as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Restructuring:

 

 

 

 

 

 

 

 

 

 

 

 

Proteomics

 

$

 

 

$

213

 

 

$

 

 

$

691

 

Genomics

 

 

 

 

 

70

 

 

 

 

 

 

629

 

Corporate expenses

 

 

2,341

 

 

 

1,715

 

 

 

12,374

 

 

 

4,095

 

Total restructuring and related charges

 

$

2,341

 

 

$

1,998

 

 

$

12,374

 

 

$

5,415